Identification

Name
Timolol
Accession Number
DB00373  (APRD00229, DB08625)
Type
Small Molecule
Groups
Approved
Description

A beta-adrenergic antagonist similar in action to propranolol. The levo-isomer is the more active. Timolol has been proposed as an antihypertensive, antiarrhythmic, antiangina, and antiglaucoma agent. It is also used in the treatment of migraine disorders and tremor. [PubChem]

Structure
Thumb
Synonyms
  • (S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
  • Timolol
  • Timolol anhydrous
  • Timololo
  • Timololum
External IDs
MK 950
Product Ingredients
IngredientUNIICASInChI Key
Timolol hemihydrate817W3C617591524-16-2TWBNMYSKRDRHAT-RCWTXCDDSA-N
Timolol maleateP8Y54F701R26921-17-5WLRMANUAADYWEA-NWASOUNVSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Beta-tim - 0.25% LiqLiquid0.25 %OphthalmicCiba Vision1994-12-311998-07-16Canada
Beta-tim - 0.5% LiqLiquid0.5 %OphthalmicCiba Vision1994-12-311998-07-16Canada
BetimolSolution / drops2.56 mg/mLOphthalmicOak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.) (968937719)2014-01-02Not applicableUs
BetimolSolution5 mg/mLOphthalmicVistakon Pharmaceuticals2000-10-01Not applicableUs
BetimolSolution / drops5.12 mg/mLOphthalmicOak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.) (968937719)2014-01-02Not applicableUs
BetimolSolution2.5 mg/mLOphthalmicVistakon Pharmaceuticals2000-10-01Not applicableUs
Blocadren Tab 10mgTablet10 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1977-12-312000-08-03Canada
Blocadren Tab 20mgTablet20 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1980-12-311999-03-02Canada
Blocadren Tab 5mgTablet5 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1978-12-312000-08-03Canada
IstalolSolution / drops5 mg/mLOphthalmicBauch & Lomb Incorporated2004-08-02Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-timopSolution0.5 %OphthalmicApotex Corporation1988-12-31Not applicableCanada
Apo-timopSolution0.25 %OphthalmicApotex Corporation1988-12-31Not applicableCanada
Apo-timop GelSolution, gel forming, extended release0.25 %OphthalmicApotex CorporationNot applicableNot applicableCanada
Apo-timop GelSolution, gel forming, extended release0.5 %OphthalmicApotex Corporation2008-02-20Not applicableCanada
Dom-timololSolution0.25 %OphthalmicDominion Pharmacal1999-03-08Not applicableCanada
Dom-timololSolution0.5 %OphthalmicDominion Pharmacal1999-03-08Not applicableCanada
Jamp-timololSolution0.5 %OphthalmicJamp Pharma Corporation2015-11-20Not applicableCanada
Mylan-timololSolution0.5 %OphthalmicMylan Pharmaceuticals1992-12-312012-10-19Canada
Mylan-timololSolution0.25 %OphthalmicMylan Pharmaceuticals1992-12-312012-10-19Canada
Novo-timol Liq 0.25%Liquid0.25 %OphthalmicNovopharm Limited1993-12-312015-10-26Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Act DorzotimololTimolol (5 mg) + Dorzolamide (20 mg)SolutionOphthalmicActavis Pharma Company2013-05-01Not applicableCanada
Act Latanoprost/timololTimolol (5 mg) + Latanoprost (50 mcg)SolutionOphthalmicActavis Pharma Company2015-09-29Not applicableCanada
Apo-brimonidine-timopTimolol (0.5 %) + Brimonidine tartrate (0.2 %)SolutionOphthalmicApotex CorporationNot applicableNot applicableCanada
Apo-dorzo-timopTimolol (5 mg) + Dorzolamide (20 mg)SolutionOphthalmicApotex Corporation2010-12-15Not applicableCanada
Apo-latanoprost-timopTimolol (5 mg) + Latanoprost (50 mcg)SolutionOphthalmicApotex Corporation2014-07-02Not applicableCanada
Apo-travoprost-timopTimolol (0.5 %) + Travoprost (0.004 %)SolutionOphthalmicApotex CorporationNot applicableNot applicableCanada
AzargaTimolol maleate (5 mg/ml) + Brinzolamide (10 mg/ml)Suspension / dropsOphthalmicNovartis Europharm Limited2008-11-25Not applicableEu
AzargaTimolol (0.5 %) + Brinzolamide (1 %)SuspensionOphthalmicNovartis2009-08-25Not applicableCanada
AzargaTimolol maleate (5 mg/ml) + Brinzolamide (10 mg/ml)Suspension / dropsOphthalmicNovartis Europharm Limited2008-11-25Not applicableEu
CombiganTimolol maleate (5 mg/mL) + Brimonidine tartrate (2 mg/mL)Solution / dropsOphthalmicAllergan2007-11-14Not applicableUs
International/Other Brands
Blocadren (Merck) / Proflax (Sidus) / Tenopt (Sigma) / Timacar Depot (MSD) / Timacor (Gerda) / Timoptol (Merck)
Categories
UNII
5JKY92S7BR
CAS number
26839-75-8
Weight
Average: 316.42
Monoisotopic: 316.156911344
Chemical Formula
C13H24N4O3S
InChI Key
BLJRIMJGRPQVNF-JTQLQIEISA-N
InChI
InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1
IUPAC Name
(2S)-1-(tert-butylamino)-3-{[4-(morpholin-4-yl)-1,2,5-thiadiazol-3-yl]oxy}propan-2-ol
SMILES
[H][[email protected]](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1

Pharmacology

Indication

In its oral form it is used to treat high blood pressure and prevent heart attacks, and occasionally to prevent migraine headaches. In its opthalmic form it is used to treat open-angle and occasionally secondary glaucoma.

Structured Indications
Pharmacodynamics

Similar to propranolol and nadolol, timolol is a non-selective, beta-adrenergic receptor antagonist. Timolol does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity, but does possess a relatively high degree of lipid solubility. Timolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage.

Mechanism of action

Like propranolol and nadolol, timolol competes with adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle and beta(2)-receptors in the bronchial and vascular smooth muscle. Beta(1)-receptor blockade results in a decrease in resting and exercise heart rate and cardiac output, a decrease in both systolic and diastolic blood pressure, and, possibly, a reduction in reflex orthostatic hypotension. Beta(2)-blockade results in an increase in peripheral vascular resistance. The exact mechanism whereby timolol reduces ocular pressure is still not known. The most likely action is by decreasing the secretion of aqueous humor.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
ABeta-2 adrenergic receptor
antagonist
Human
ULysozymeNot AvailableEnterobacteria phage T4
Absorption

Bioavailability is about 60%

Volume of distribution
Not Available
Protein binding

~10%

Metabolism

Primarily hepatic (80%) via the cytochrome P450 2D6 isoenzyme.

Route of elimination

Timolol and its metabolites are primarily excreted in the urine.

Half life

2.5-5 hours

Clearance
Not Available
Toxicity

LD50=1190 mg/kg (oral, mice), LD50=900 mg/kg (oral, rat). Symptoms of overdose include drowsiness, vertigo, headache, and atriventricular block.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Timolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Timolol.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Timolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Timolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Timolol.Experimental
AbirateroneThe serum concentration of Timolol can be increased when it is combined with Abiraterone.Approved
AcebutololTimolol may increase the hypotensive activities of Acebutolol.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Timolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Timolol can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineAcepromazine may increase the hypotensive activities of Timolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Timolol.Approved
AcetohexamideTimolol may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Timolol is combined with Acetylcholine.Approved
AcetyldigitoxinTimolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinTimolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Timolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Timolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Timolol.Experimental, Investigational
AlaproclateThe serum concentration of Timolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Timolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Timolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Timolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Timolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Timolol.Approved, Vet Approved
AliskirenTimolol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Timolol.Experimental
AlprenololTimolol may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Timolol.Approved
AmbrisentanTimolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineTimolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Timolol is combined with Amiloride.Approved
AmiodaroneThe therapeutic efficacy of Timolol can be increased when used in combination with Amiodarone.Approved, Investigational
AmlodipineTimolol may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe serum concentration of Timolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Timolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Timolol.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Timolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Timolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Timolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Timolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Timolol.Approved, Investigational
ApalutamideThe serum concentration of Timolol can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Timolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Timolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Timolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Timolol is combined with Arecoline.Experimental
AripiprazoleAripiprazole may increase the hypotensive activities of Timolol.Approved, Investigational
ArmodafinilThe metabolism of Timolol can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Timolol.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Timolol.Approved, Investigational
ArtemetherThe metabolism of Timolol can be decreased when combined with Artemether.Approved
AtenololAtenolol may increase the hypotensive activities of Timolol.Approved
AtomoxetineThe metabolism of Timolol can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Timolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Timolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Timolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Timolol is combined with Azilsartan medoxomil.Approved, Investigational
BalsalazideBalsalazide may decrease the antihypertensive activities of Timolol.Approved, Investigational
BarbexacloneThe serum concentration of Timolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Timolol can be decreased when it is combined with Barbital.Illicit
BarnidipineTimolol may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilTimolol may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Timolol.Experimental
BendroflumethiazideTimolol may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Timolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Timolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Timolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Timolol.Approved
BepridilTimolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantTimolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe metabolism of Timolol can be decreased when combined with Betaxolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Timolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Timolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Timolol.Experimental
BimatoprostTimolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololTimolol may increase the hypotensive activities of Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Timolol.Investigational
BortezomibThe metabolism of Timolol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Timolol.Approved, Investigational
BQ-123Timolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Timolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Timolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Timolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Timolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Timolol.Investigational
BucindololTimolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Timolol.Approved, Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Timolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Timolol is combined with Bumetanide.Approved
BunazosinTimolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Timolol.Approved, Investigational
BupranololTimolol may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Timolol can be decreased when combined with Bupropion.Approved
CabergolineTimolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Timolol.Experimental
CafedrineTimolol may increase the hypotensive activities of Cafedrine.Investigational
CalfactantTimolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Timolol is combined with Canagliflozin.Approved
CandesartanTimolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilTimolol may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilTimolol may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilTimolol may increase the hypotensive activities of Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Timolol is combined with Carbachol.Approved
CarbamazepineThe metabolism of Timolol can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Timolol.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Timolol.Approved, Investigational
CarbutamideTimolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Timolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Timolol.Approved, Vet Approved, Withdrawn
CarteololTimolol may increase the hypotensive activities of Carteolol.Approved
CarvedilolTimolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Timolol.Experimental
CelecoxibThe metabolism of Timolol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololTimolol may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibTimolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Timolol is combined with Cevimeline.Approved
ChloramphenicolThe metabolism of Timolol can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Timolol can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideTimolol may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Timolol.Experimental
ChlorpromazineThe metabolism of Timolol can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideTimolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Timolol.Approved
CholecalciferolThe metabolism of Timolol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Timolol.Approved
CicletanineTimolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilTimolol may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Timolol.Approved, Investigational
CimetidineThe metabolism of Timolol can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Timolol can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Timolol can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Timolol can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Timolol is combined with Clevidipine.Approved, Investigational
ClobazamThe metabolism of Timolol can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Timolol.Approved, Investigational
ClomipramineThe metabolism of Timolol can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Timolol.Approved
CloranololTimolol may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Timolol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Timolol can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Timolol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Timolol can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Timolol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Timolol.Vet Approved
CrizotinibTimolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineTimolol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Timolol.Approved, Investigational
CyclopenthiazideTimolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideTimolol may increase the hypotensive activities of Cyclothiazide.Approved
CymarinTimolol may increase the bradycardic activities of Cymarin.Experimental
DabrafenibThe serum concentration of Timolol can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Timolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Timolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Timolol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Timolol can be increased when it is combined with Darunavir.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Timolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Timolol.Approved
DelaprilTimolol may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Timolol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Timolol.Approved
DeserpidineTimolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Timolol.Approved
DesipramineThe metabolism of Timolol can be decreased when combined with Desipramine.Approved, Investigational
DeslanosideTimolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Timolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Timolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Timolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Timolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Timolol is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineTimolol may increase the hypotensive activities of Diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Timolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Timolol.Approved, Investigational
DigitoxinTimolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinTimolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Timolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Timolol.Approved, Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Timolol.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Timolol is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe metabolism of Timolol can be decreased when combined with Diphenhydramine.Approved, Investigational
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Timolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Timolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Timolol.Experimental
DonepezilDonepezil may increase the bradycardic activities of Timolol.Approved
DorzolamideTimolol may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Timolol can be decreased when combined with Dosulepin.Approved
DoxazosinTimolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Timolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Timolol.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational
DuloxetineTimolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Timolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Timolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Timolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Timolol.Approved
EfavirenzThe metabolism of Timolol can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineTimolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
EliglustatThe metabolism of Timolol can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Timolol is combined with Empagliflozin.Approved
EnalaprilTimolol may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTimolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Timolol.Experimental
EpanololTimolol may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Timolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Timolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Timolol is combined with Eplerenone.Approved
EpoprostenolTimolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanTimolol may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateTimolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineTimolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
Eslicarbazepine acetateThe metabolism of Timolol can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Timolol.Approved
EsomeprazoleThe metabolism of Timolol can be decreased when combined with Esomeprazole.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Timolol is combined with Etacrynic acid.Approved, Investigational
EtanerceptEtanercept may decrease the antihypertensive activities of Timolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Timolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Timolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Timolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
EtoperidoneThe serum concentration of Timolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Timolol.Approved, Investigational
EtravirineThe metabolism of Timolol can be decreased when combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Timolol.Approved, Investigational
ExisulindExisulind may decrease the antihypertensive activities of Timolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Timolol.Experimental
FelodipineTimolol may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Timolol.Approved
FenoldopamTimolol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Timolol.Approved
FentanylFentanyl may increase the bradycardic activities of Timolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Timolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Timolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Timolol.Experimental
Ferulic acidTimolol may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Timolol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Timolol.Approved, Investigational
FingolimodTimolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Timolol is combined with Floctafenine.Approved, Withdrawn
FluconazoleThe metabolism of Timolol can be decreased when combined with Fluconazole.Approved, Investigational
FlunixinFlunixin may decrease the antihypertensive activities of Timolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Timolol.Experimental
FluoxetineThe metabolism of Timolol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Timolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Timolol.Approved, Investigational
FluvoxamineThe metabolism of Timolol can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilTimolol may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe metabolism of Timolol can be increased when combined with Fosphenytoin.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Timolol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Timolol is combined with Furosemide.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Timolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Timolol.Approved
GemfibrozilThe metabolism of Timolol can be decreased when combined with Gemfibrozil.Approved
GitoformateTimolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideTimolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideTimolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideTimolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideTimolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneTimolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideTimolol may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideTimolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Timolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Timolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Timolol.Approved
GuanazodineTimolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineTimolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational
GuanoclorTimolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTimolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTimolol may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe metabolism of Timolol can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Timolol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Timolol.Experimental
HexamethoniumTimolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe serum concentration of Timolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Timolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Timolol.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Timolol.Experimental
HydralazineHydralazine may increase the hypotensive activities of Timolol.Approved
HydrochlorothiazideTimolol may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideTimolol may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxychloroquineThe metabolism of Timolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Timolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Timolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Timolol.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Timolol.Approved, Investigational
ImidaprilTimolol may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Timolol.Experimental
ImipramineThe metabolism of Timolol can be decreased when combined with Imipramine.Approved
IndalpineThe serum concentration of Timolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideTimolol may increase the hypotensive activities of Indapamide.Approved
IndenololTimolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Timolol can be decreased when combined with Indinavir.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Timolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Timolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Timolol.Withdrawn
IndoraminTimolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanTimolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkTimolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Timolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Timolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Timolol.Withdrawn
IrbesartanTimolol may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Timolol can be increased when it is combined with Isavuconazole.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Timolol.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Timolol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Timolol.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Timolol can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Timolol is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Timolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Timolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Timolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Timolol.Approved, Investigational
IvabradineTimolol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Timolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Timolol.Investigational
KetoconazoleThe metabolism of Timolol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Timolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Timolol.Approved
LabetalolTimolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineTimolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideTimolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CTimolol may increase the bradycardic activities of Lanatoside C.Experimental
LanreotideTimolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostTimolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Timolol.Approved, Investigational
LercanidipineTimolol may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Timolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Timolol.Approved, Investigational
LevodopaTimolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Timolol can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Timolol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Timolol.Approved, Vet Approved
LinsidomineTimolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilTimolol may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Timolol.Investigational
LobeglitazoneThe metabolism of Timolol can be decreased when combined with Lobeglitazone.Approved, Investigational
LobelineThe risk or severity of adverse effects can be increased when Timolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Timolol.Experimental
LopinavirThe metabolism of Timolol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Timolol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Timolol.Approved, Investigational
LosartanTimolol may increase the hypotensive activities of Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Timolol.Approved, Investigational
LucinactantTimolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Timolol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Timolol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Timolol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Timolol.Approved, Investigational
MacitentanTimolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Timolol.Approved
MalathionMalathion may increase the bradycardic activities of Timolol.Approved, Investigational
ManidipineTimolol may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Timolol is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Timolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Timolol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Timolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Timolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Timolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Timolol.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Timolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Timolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Timolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Timolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Timolol.Approved, Investigational
MetahexamideTimolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Timolol.Approved, Investigational, Withdrawn
MethacholineTimolol may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethadoneThe metabolism of Timolol can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Timolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Timolol is combined with Methazolamide.Approved
MethohexitalThe serum concentration of Timolol can be decreased when it is combined with Methohexital.Approved
MethoserpidineTimolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Timolol can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Timolol.Approved
MethyldopaTimolol may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Timolol.Approved, Investigational
MethylergometrineTimolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Timolol.Approved, Investigational
MethylphenobarbitalThe serum concentration of Timolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinTimolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololTimolol may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Timolol.Approved, Investigational
MetolazoneTimolol may increase the hypotensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Timolol.Approved, Investigational
MetyrosineTimolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilTimolol may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineTimolol may increase the bradycardic activities of Midodrine.Approved
MidostaurinThe metabolism of Timolol can be decreased when combined with Midostaurin.Approved, Investigational
MilnacipranThe serum concentration of Timolol can be increased when it is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Timolol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Timolol.Approved, Investigational
MirabegronThe metabolism of Timolol can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Timolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Timolol.Investigational
MoclobemideThe metabolism of Timolol can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Timolol can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilTimolol may increase the hypotensive activities of Moexipril.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Timolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Timolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Timolol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Timolol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational
MuzolimineTimolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Timolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Timolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Timolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Timolol.Approved
NadololTimolol may increase the hypotensive activities of Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Timolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Timolol.Approved
NaftopidilTimolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Timolol.Approved, Vet Approved
NebivololTimolol may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Timolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Timolol can be decreased when combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Timolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Timolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Timolol is combined with Nesiritide.Approved, Investigational
NevirapineThe metabolism of Timolol can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Timolol.Withdrawn
NicardipineThe metabolism of Timolol can be decreased when combined with Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Timolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Timolol is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Timolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Timolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Timolol.Approved
NiguldipineTimolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Timolol can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineTimolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Timolol.Approved, Investigational, Withdrawn
NimodipineTimolol may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineTimolol may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineTimolol may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Timolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Timolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Timolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Timolol.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Timolol.Approved, Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
ObinutuzumabTimolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Timolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Timolol.Approved, Investigational
OleandrinTimolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Timolol.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Timolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Timolol.Approved
OmapatrilatTimolol may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Timolol can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Timolol.Vet Approved
OuabainTimolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Timolol.Approved
OxprenololTimolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Timolol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Timolol.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
PanobinostatThe serum concentration of Timolol can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Timolol can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Timolol is combined with Papaverine.Approved, Investigational
ParaoxonParaoxon may increase the bradycardic activities of Timolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Timolol.Approved
PargylinePargyline may increase the hypotensive activities of Timolol.Approved
ParoxetineThe metabolism of Timolol can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Timolol.Approved, Investigational
PasireotideTimolol may increase the bradycardic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Timolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololTimolol may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe serum concentration of Timolol can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumTimolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Timolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Timolol.Approved, Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilTimolol may increase the hypotensive activities of Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Timolol.Approved
PeruvosideTimolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Timolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Timolol.Withdrawn
PhenobarbitalThe serum concentration of Timolol can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineTimolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Timolol.Withdrawn
PhentolamineTimolol may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Timolol.Approved, Vet Approved
PhenytoinThe metabolism of Timolol can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Timolol.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Timolol is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Timolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Timolol.Approved
PindololTimolol may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Timolol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Timolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Timolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Timolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Timolol.Experimental
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Timolol.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Timolol.Withdrawn
Platelet Activating FactorTimolol may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideTimolol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaTimolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Timolol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Timolol.Experimental, Investigational
PrazosinTimolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Timolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Timolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Timolol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Timolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Timolol.Experimental
PromazineThe metabolism of Timolol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Timolol.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Timolol.Approved, Investigational
PropafenoneThe serum concentration of Timolol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Timolol.Approved, Investigational
PropiopromazinePropiopromazine may increase the hypotensive activities of Timolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Timolol.Approved, Investigational, Vet Approved
PropranololTimolol may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Timolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Timolol.Experimental
ProscillaridinTimolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Timolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Timolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Timolol is combined with Quetiapine.Approved
QuinaprilTimolol may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe metabolism of Timolol can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Timolol can be decreased when combined with Quinine.Approved
RacepinephrineRacepinephrine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
RamiprilRamipril may increase the hypotensive activities of Timolol.Approved
RanolazineThe serum concentration of Timolol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Timolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Timolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Timolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Timolol.Approved
RescinnamineTimolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Timolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Timolol.Approved, Experimental, Investigational
RifampicinThe metabolism of Timolol can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Timolol can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Timolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Timolol.Approved, Investigational
RiociguatTimolol may increase the hypotensive activities of Riociguat.Approved
RisperidoneTimolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Timolol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabTimolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineTimolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Timolol.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Timolol can be decreased when combined with Rolapitant.Approved, Investigational
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Timolol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Timolol.Approved
RucaparibThe metabolism of Timolol can be decreased when combined with Rucaparib.Approved, Investigational
RuxolitinibRuxolitinib may increase the bradycardic activities of Timolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Timolol.Approved
SafrazineSafrazine may increase the hypotensive activities of Timolol.Withdrawn
SalicylamideSalicylamide may decrease the antihypertensive activities of Timolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Timolol.Approved, Investigational, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Timolol.Approved
SaprisartanTimolol may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalThe serum concentration of Timolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Timolol.Approved, Investigational, Vet Approved
SelexipagTimolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Timolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Timolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Timolol.Investigational
SertralineThe metabolism of Timolol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Timolol.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Timolol.Approved, Investigational
SilodosinTimolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanTimolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SotalolThe risk or severity of adverse effects can be increased when Timolol is combined with Sotalol.Approved
SpiraprilTimolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Timolol is combined with Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Timolol.Investigational
StiripentolThe metabolism of Timolol can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Timolol.Approved, Investigational
SufentanilSufentanil may increase the bradycardic activities of Timolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Timolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Timolol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Timolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Timolol.Experimental
TacrineTacrine may increase the bradycardic activities of Timolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Timolol.Approved, Investigational
TalinololTimolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinTimolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Timolol.Investigational
TelmisartanTimolol may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilTimolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Timolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Timolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Timolol.Vet Approved
TerazosinTimolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Timolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Timolol.Approved
TerlipressinTimolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineTimolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Timolol.Approved, Investigational, Withdrawn
TheodrenalineTimolol may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe serum concentration of Timolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Timolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Timolol.Withdrawn
ThiopentalThe serum concentration of Timolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Timolol.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Timolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Timolol.Approved
TiboloneTimolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Timolol can be decreased when combined with Ticlopidine.Approved
TicrynafenTimolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TinoridineTinoridine may decrease the antihypertensive activities of Timolol.Investigational
TipranavirThe metabolism of Timolol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational
TofacitinibTofacitinib may increase the bradycardic activities of Timolol.Approved, Investigational
TolazamideTimolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineTimolol may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideTimolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Timolol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Timolol.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Timolol.Approved
TolonidineTimolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Timolol.Approved
TopiramateThe metabolism of Timolol can be decreased when combined with Topiramate.Approved
TorasemideTorasemide may increase the hypotensive activities of Timolol.Approved
TrandolaprilTimolol may increase the hypotensive activities of Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Timolol.Approved, Investigational
TranylcypromineThe metabolism of Timolol can be decreased when combined with Tranylcypromine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Timolol.Approved
TreprostinilTimolol may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Timolol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Timolol is combined with Triamterene.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Timolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Timolol.Vet Approved
TrichlormethiazideTimolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Timolol.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Timolol.Approved, Vet Approved
TrimazosinTimolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Timolol.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Timolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Timolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Timolol.Approved, Investigational
UnoprostoneTimolol may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilTimolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Timolol.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Timolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Timolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Timolol is combined with Varenicline.Approved, Investigational
VemurafenibThe serum concentration of Timolol can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Timolol can be decreased when combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Timolol.Approved
VincamineTimolol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTimolol may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Timolol can be decreased when combined with Voriconazole.Approved, Investigational
XipamideTimolol may increase the hypotensive activities of Xipamide.Experimental
XylazineXylazine may increase the atrioventricular blocking (AV block) activities of Timolol.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Timolol.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Timolol.Approved, Investigational, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Timolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Timolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Timolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Timolol can be decreased when combined with Ziprasidone.Approved
ZofenoprilTimolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Timolol.Withdrawn
ZucapsaicinThe metabolism of Timolol can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Markku Per alampi, "S-timolol hemihydrate composition and method of preparation therefor." U.S. Patent US5574035, issued October, 1986.

US5574035
General References
  1. Link [Link]
External Links
KEGG Compound
C07141
PubChem Compound
33624
PubChem Substance
46507733
ChemSpider
31013
BindingDB
50292219
ChEBI
9599
ChEMBL
CHEMBL499
Therapeutic Targets Database
DAP000088
PharmGKB
PA451690
HET
TIM
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Timolol
ATC Codes
C07DA06 — Timolol, thiazides and other diureticsS01ED51 — Timolol, combinationsS01ED01 — TimololC07AA06 — TimololC07BA06 — Timolol and thiazides
AHFS Codes
  • 52:40.08 — Beta-adrenergic Agents
  • 24:24.00 — Beta-adrenergic Blocking Agents
  • 52:92.00 — EENT Drugs, Miscellaneous
PDB Entries
3d4s
FDA label
Download (471 KB)
MSDS
Download (73.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedOtherGlaucoma / Ophthalmic Solutions1
0Unknown StatusTreatmentHemangiomas / Infants1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentEye Diseases / Glaucoma / Ocular Hypertension1
1CompletedTreatmentGlaucoma1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
1RecruitingTreatmentAcne Vulgaris / Rosaceas1
1RecruitingTreatmentGlaucoma1
1RecruitingTreatmentPort-wine Mark / Sturge Weber Syndrome1
1TerminatedPreventionInfantile Hemangiomas / Very Low Birth Weight Infants1
1WithdrawnTreatmentAnterior Ischemic Optic Neuropathy / Ischemic Optic Neuropathy / Optic Neuropathy, Anterior Ischemic / Optic Neuropathy, Ischemic1
1, 2CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)3
1, 2Unknown StatusTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
2Active Not RecruitingTreatmentGlaucoma Open-Angle1
2Active Not RecruitingTreatmentGlaucoma and Ocular Hypertension1
2CompletedPreventionEsophageal and Gastric Varices / Liver Cirrhosis / Portal Hypertension1
2CompletedTreatmentAge-Related Macular Degeneration (ARMD) / Diabetic Macular Edema (DME) / Retinal Vein Occlusions(RVO) / Wet Macular Degeneration1
2CompletedTreatmentGlaucoma3
2CompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension4
2CompletedTreatmentGlaucoma / Ocular Hypertension2
2CompletedTreatmentHemangiomas1
2CompletedTreatmentHemorrhagic Hereditary Telangiectasia (HHT)1
2CompletedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)2
2CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)3
2CompletedTreatmentOpen Angle Glaucoma (OAG)1
2Not Yet RecruitingNot AvailableHealthy Volunteers1
2RecruitingTreatmentHemangiomas1
2RecruitingTreatmentVenous Leg Ulcer (VLU)1
2TerminatedTreatmentMinor burns / Ulcers1
2Unknown StatusTreatmentHypertensive Phase1
2WithdrawnTreatmentInfantile Hemangiomas1
2, 3CompletedBasic ScienceOpen-angle Glaucoma (OAG)1
2, 3RecruitingTreatmentNeovascular Age-Related Macular Degeneration / Wet Macular Degeneration1
3Active Not RecruitingTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
3CompletedPreventionEsophageal and Gastric Varices / Liver Cirrhosis / Portal Hypertension1
3CompletedTreatmentGlaucoma3
3CompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension4
3CompletedTreatmentGlaucoma / Ocular Hypertension8
3CompletedTreatmentGlaucoma / Ocular Hypertension / Open Angle Glaucoma (OAG)1
3CompletedTreatmentGlaucoma / Ocular Hypertension / Open-angle Glaucoma (OAG)1
3CompletedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)6
3CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)18
3CompletedTreatmentOpen Angle Glaucoma or Ocular Hypertension1
3Not Yet RecruitingTreatmentChronic Diabetic Foot Ulcers / Diabetic Neuropathic Ulcers / Non Healing Wound1
3Not Yet RecruitingTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
3RecruitingPreventionGlaucoma1
3RecruitingTreatmentGlaucoma, Primary Open Angle (POAG)1
3RecruitingTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
3TerminatedBasic ScienceHealthy Volunteers1
3TerminatedTreatmentGlaucoma1
3TerminatedTreatmentGlaucoma / Ocular Hypertension1
3TerminatedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)1
3Unknown StatusTreatmentCorneal Edema / Visual Acuity1
3Unknown StatusTreatmentGlaucoma2
3Unknown StatusTreatmentMelanoma1
3WithdrawnPreventionHemorrhage, Gastrointestinal / Portal Hypertension1
4CompletedNot AvailableOcular Hypertension / Open-angle Glaucoma (OAG)1
4CompletedNot AvailableOpen-angle Glaucoma (OAG)1
4CompletedBasic ScienceGlaucoma1
4CompletedOtherEye Disease1
4CompletedTreatmentAnterior Uveitis (AU) / Cystoid Macular Edema1
4CompletedTreatmentExfoliation Syndrome / Ocular Hypertension / Open-angle Glaucoma (OAG) / Pigmentary Glaucoma1
4CompletedTreatmentEye Diseases / Glaucoma / Open-angle Glaucoma (OAG)1
4CompletedTreatmentGlaucoma12
4CompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
4CompletedTreatmentGlaucoma / Ocular Hypertension9
4CompletedTreatmentGlaucoma / Ocular Hypertension / Open-angle Glaucoma (OAG)1
4CompletedTreatmentGlaucoma / Ocular Surface Disease1
4CompletedTreatmentOcular Hypertension1
4CompletedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)3
4CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)8
4CompletedTreatmentOpen Angle Glaucoma (OAG)1
4CompletedTreatmentOpen-angle Glaucoma (OAG)1
4RecruitingDiagnosticGlaucoma, Primary Open Angle (POAG) / Glaucoma; Drugs / Normal Tension Glaucoma1
4RecruitingTreatmentGlaucoma1
4TerminatedTreatmentGlaucoma1
4TerminatedTreatmentGlaucoma, Angle-Closure1
4TerminatedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
4Unknown StatusBasic ScienceOpen Angle Glaucoma (OAG)1
4Unknown StatusTreatmentGlaucoma1
4Unknown StatusTreatmentNormal Tension Glaucoma1
4WithdrawnPreventionGlaucoma / Ocular Hypertension / Thyroid Eye Disease1
4WithdrawnTreatmentBenign Vascular Periocular Lesions1
Not AvailableCompletedNot AvailableGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
Not AvailableCompletedNot AvailableGlaucoma / Ocular Hypertension2
Not AvailableCompletedNot AvailableOcular Hypertension / Open-angle Glaucoma (OAG)4
Not AvailableCompletedBasic ScienceDrug Effect (Glaucoma Drugs)1
Not AvailableCompletedBasic ScienceGlaucoma1
Not AvailableCompletedPreventionIntraocular Pressure Change in Intravitreal Injection1
Not AvailableCompletedTreatmentGlaucoma / Ocular Hypertension1
Not AvailableCompletedTreatmentMacular Hole / Retinal Detachment1
Not AvailableCompletedTreatmentMyopic Regression1
Not AvailableCompletedTreatmentNormal Tension Glaucoma1
Not AvailableCompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
Not AvailableCompletedTreatmentPhysiology, Ocular / Retina1
Not AvailableNot Yet RecruitingPreventionOcular Hypertension1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingPreventionHemangiomas1
Not AvailableRecruitingTreatmentComplications of Diabetes Mellitus1
Not AvailableRecruitingTreatmentHereditary Haemorrhagic Telangiectasia (HHT)1
Not AvailableUnknown StatusHealth Services ResearchOpen Angle Glaucoma (OAG)1
Not AvailableUnknown StatusTreatmentExfoliation Syndrome / Glaucoma / Ocular Hypertension1
Not AvailableWithdrawnNot AvailableOcular Hypertension / Open-angle Glaucoma (OAG)1
Not AvailableWithdrawnBasic ScienceGlaucoma1

Pharmacoeconomics

Manufacturers
  • Santen oy
  • Falcon pharmaceuticals ltd
  • Aton pharma inc
  • Ista pharmaceuticals
  • Akorn inc
  • Bausch and lomb pharmaceuticals inc
  • Bausch and lomb inc
  • Falcon pharmaceuticals inc
  • Fdc ltd
  • E fougera div altana inc
  • Hi tech pharmacal co inc
  • Novex pharma
  • Pacific pharma inc
  • Pacific pharma
  • Wockhardt ltd
  • Merck research laboratories div merck co inc
  • Mylan pharmaceuticals inc
  • Quantum pharmics ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Watson laboratories inc
Packagers
  • Akorn Inc.
  • Alcon Laboratories
  • Allergan Inc.
  • Apotex Inc.
  • A-S Medication Solutions LLC
  • Aton Pharma Inc.
  • Bausch & Lomb Inc.
  • Dispensing Solutions
  • E. Fougera and Co.
  • Endo Pharmaceuticals Inc.
  • Falcon Pharmaceuticals Ltd.
  • Hi Tech Pharmacal Co. Inc.
  • ISTA Pharmaceuticals
  • Major Pharmaceuticals
  • Medisca Inc.
  • Merck & Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novex Pharma
  • Novopharm Ltd.
  • Pacific Pharma Lp
  • Pack Pharmaceuticals
  • Palmetto Pharmaceuticals Inc.
  • PCAS Finland Oy
  • Person & Covey
  • Pharmedix
  • Physicians Total Care Inc.
  • Prasco Labs
  • Qualitest
  • Sandhills Packaging Inc.
  • Sandoz
  • Santen Inc.
  • Vistakon Pharmaceuticals LLC
Dosage forms
FormRouteStrength
SuspensionOphthalmic
Suspension / dropsOphthalmic
LiquidOphthalmic0.25 %
LiquidOphthalmic0.5 %
Solution / dropsOphthalmic2.56 mg/mL
Solution / dropsOphthalmic5.12 mg/mL
SolutionOphthalmic
Solution / dropsOphthalmic
SolutionOphthalmic0.25 %
SolutionOphthalmic0.5 %
TabletOral10 mg
TabletOral20 mg
TabletOral5 mg
TabletOral
Solution, gel forming, extended releaseOphthalmic2.5 mg/mL
Solution, gel forming, extended releaseOphthalmic5 mg/mL
SolutionOphthalmic6.8 mg/mL
Solution / dropsOphthalmic2.5 mg/mL
Solution / dropsOphthalmic5 mg/mL
Solution / dropsOphthalmic6.8 mg/mL
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
SolutionOphthalmic.25 %
SolutionOphthalmic3.4 mg/mL
SolutionOphthalmic2.5 mg/mL
SolutionOphthalmic5 mg/mL
Solution, gel forming, extended releaseOphthalmic0.25 %
Solution, gel forming, extended releaseOphthalmic0.5 %
Prices
Unit descriptionCostUnit
Betimol 0.5% Solution 15ml Bottle152.24USD bottle
Timolol maleate powder107.1USD g
Betimol 0.5% Solution 10ml Bottle106.88USD bottle
Betimol 0.25% Solution 15ml Bottle93.56USD bottle
Timoptic-XE 0.5% Gel Forming Solution 5ml Bottle85.09USD bottle
Timoptic 0.5% Solution 10ml Bottle83.2USD bottle
Timoptic-XE 0.25% Gel Forming Solution 5ml Bottle65.37USD bottle
Betimol 0.5% Solution 5ml Bottle63.43USD bottle
Timolol Maleate 0.5% Gel Forming Solution 5ml Bottle60.84USD bottle
Timoptic 0.5% Solution 5ml Bottle59.8USD bottle
Timolol Maleate 0.25% Gel Forming Solution 5ml Bottle59.71USD bottle
Betimol 0.25% Solution 5ml Bottle55.56USD bottle
Timolol Maleate 0.5% Solution 15ml Bottle50.7USD bottle
Betimol 0.25% Solution 10ml Bottle49.99USD bottle
Timolol Maleate 0.5% Gel Forming Solution 2.5ml Bottle46.74USD bottle
Timolol Maleate 0.25% Solution 15ml Bottle43.68USD bottle
Timoptic 0.25% Solution 5ml Bottle43.06USD bottle
Istalol 0.5% eye drops36.43USD ml
Timolol Maleate 0.5% Solution 10ml Bottle33.58USD bottle
Timolol Maleate 0.25% Solution 10ml Bottle28.87USD bottle
Timoptic-XE 0.25% Gel Forming Solution 2.5ml Bottle23.99USD bottle
Timolol Maleate 0.5% Solution 5ml Bottle17.68USD bottle
Timolol Maleate 0.25% Solution 5ml Bottle15.6USD bottle
Timoptic-xe 0.5% eye solution13.6USD ml
Timoptic-xe 0.25% eye solution11.51USD ml
Betimol 0.5% eye drops10.15USD ml
Betimol 0.25% eye drops9.19USD ml
Timoptic 0.5% eye drops8.63USD ml
Timoptic 0.25% eye drops7.32USD ml
Timoptic-Xe 0.5 % Long Acting Gellan Solution4.64USD ml
Timoptic 0.5% ocudose drops4.57USD each
Timoptic-Xe 0.25 % Long Acting Gellan Solution3.88USD ml
Timoptic 0.25% ocudose drops3.8USD each
Timoptic 0.5 % Solution3.63USD ml
Timolol 0.5% eye drops3.24USD ml
Timolol 0.25% eye drops2.78USD ml
Apo-Timop 0.5 % Solution1.95USD ml
Mylan-Timolol 0.5 % Solution1.95USD ml
Pms-Timolol 0.5 % Solution1.95USD ml
Sandoz Timolol Maleate 0.5 % Solution1.95USD ml
Apo-Timop 0.25 % Solution1.62USD ml
Mylan-Timolol 0.25 % Solution1.62USD ml
Pms-Timolol 0.25 % Solution1.62USD ml
Sandoz Timolol Maleate 0.25 % Solution1.62USD ml
Timolol maleate 20 mg tablet0.94USD tablet
Hydrocortisone 2.5% lotion0.6USD ml
Apo-Timol 20 mg Tablet0.59USD tablet
Novo-Timol 20 mg Tablet0.59USD tablet
Timolol maleate 10 mg tablet0.51USD tablet
Timolol maleate 5 mg tablet0.41USD tablet
Apo-Timol 10 mg Tablet0.3USD tablet
Novo-Timol 10 mg Tablet0.3USD tablet
Nu-Timolol 10 mg Tablet0.3USD tablet
Apo-Timol 5 mg Tablet0.19USD tablet
Novo-Timol 5 mg Tablet0.19USD tablet
Nu-Timolol 5 mg Tablet0.19USD tablet
Aquanil hc 1% lotion0.12USD ml
Aquanil cleanser0.03USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5231095No1993-07-272010-07-27Us
US6174524Yes1999-09-262019-09-26Us
US7030149No2002-04-192022-04-19Us
US7320976No2002-04-192022-04-19Us
US7642258No2002-04-192022-04-19Us
US8133890No2002-04-192022-04-19Us
US8354409No2002-04-192022-04-19Us
US8748425No2002-04-192022-04-19Us
US7323463No2003-01-192023-01-19Us
US6335335No1998-11-022018-11-02Us
US6645963No1998-11-162018-11-16Us
US9474751No2002-04-192022-04-19Us
US9770453No2002-04-192022-04-19Us
US9907801No2002-04-192022-04-19Us
US9907802No2002-04-192022-04-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)202 °CPhysProp
water solubility2.74 mg/mLNot Available
logP1.83HANSCH,C ET AL. (1995)
Caco2 permeability-4.85ADME Research, USCD
pKa9.21KONTTURI,K & MURTOMAKI,L (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.269 mg/mLALOGPS
logP1.44ALOGPS
logP1.34ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.08ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area79.74 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity83.92 m3·mol-1ChemAxon
Polarizability33.86 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9958
Blood Brain Barrier-0.6467
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.8522
P-glycoprotein inhibitor INon-inhibitor0.6567
P-glycoprotein inhibitor IINon-inhibitor0.9552
Renal organic cation transporterNon-inhibitor0.9105
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5389
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8678
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7338
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6096 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9214
hERG inhibition (predictor II)Non-inhibitor0.7334
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0009000000-d71d621ed511e13fd0fc
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-02t9-0069000000-b1978af1db9940bfb5e5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-01vx-4390000000-df83be04a7e7c18de424
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-9410000000-c9b47edd2cfab49a0aef
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-9300000000-617e94c43fe73fa575e6
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-03di-0090000000-da0c1e25ae5110879b00
MS/MS Spectrum - , positiveLC-MS/MSsplash10-02t9-0379000000-8b822b96645d698d2c82

Taxonomy

Description
This compound belongs to the class of organic compounds known as dialkylarylamines. These are aliphatic aromatic amines in which the amino group is linked to two aliphatic chains and one aromatic group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Dialkylarylamines
Alternative Parents
Alkyl aryl ethers / Morpholines / Imidolactams / Thiadiazoles / Heteroaromatic compounds / Secondary alcohols / 1,2-aminoalcohols / Oxacyclic compounds / Dialkylamines / Dialkyl ethers
show 3 more
Substituents
Dialkylarylamine / Alkyl aryl ether / Morpholine / Oxazinane / Imidolactam / Azole / Heteroaromatic compound / Thiadiazole / 1,2-aminoalcohol / Secondary alcohol
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
timolol (CHEBI:9599)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Nieminen T, Uusitalo H, Maenpaa J, Turjanmaa V, Rane A, Lundgren S, Ropo A, Rontu R, Lehtimaki T, Kahonen M: Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol. 2005 Dec;61(11):811-9. Epub 2005 Nov 17. [PubMed:16315032]
  3. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496]
  4. Hirooka K, Kelly ME, Baldridge WH, Barnes S: Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp Eye Res. 2000 May;70(5):611-21. [PubMed:10870519]
  5. Bhattacharyya BJ, Lee E, Krupin D, Hockberger P, Krupin T: (-)-Isoproterenol modulation of maxi-K(+) channel in nonpigmented ciliary epithelial cells through a G-protein gated pathway. Curr Eye Res. 2002 Mar;24(3):173-81. [PubMed:12221524]
  6. Wang T, Kaumann AJ, Brown MJ: (--)-Timolol is a more potent antagonist of the positive inotropic effects of (--)-adrenaline than of those of (--)-noradrenaline in human atrium. Br J Clin Pharmacol. 1996 Aug;42(2):217-23. [PubMed:8864321]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Fuchsjager-Mayrl G, Markovic O, Losert D, Lucas T, Wachek V, Muller M, Schmetterer L: Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects. Mol Vis. 2005 Sep 23;11:811-5. [PubMed:16205624]
  3. Rotmensch HH, Vlasses PH, Feinberg JA, Abrams WB, Ferguson RK: Comparisons of beta-adrenergic blocking properties of S- and R-timolol in humans. J Clin Pharmacol. 1993 Jun;33(6):544-8. [PubMed:8103526]
  4. Borger P, Hoekstra Y, Esselink MT, Postma DS, Zaagsma J, Vellenga E, Kauffman HF: Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype. Am J Respir Cell Mol Biol. 1998 Sep;19(3):400-7. [PubMed:9730867]
  5. Van der Graaf PH, Saxena PR, Shankley NP, Black JW: Exposure and characterization of the action of noradrenaline at dopamine receptors mediating endothelium-independent relaxation of rat isolated small mesenteric arteries. Br J Pharmacol. 1995 Dec;116(8):3237-42. [PubMed:8719802]
  6. Ferro A, Hall JA, Dickerson JE, Brown MJ: A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects. Br J Clin Pharmacol. 1997 Mar;43(3):301-8. [PubMed:9088585]
  7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Enterobacteria phage T4
Pharmacological action
Unknown
General Function
Lysozyme activity
Specific Function
Endolysin with lysozyme activity that degrades host peptidoglycans and participates with the holin and spanin proteins in the sequential events which lead to the programmed host cell lysis releasin...
Gene Name
E
Uniprot ID
P00720
Uniprot Name
Endolysin
Molecular Weight
18691.385 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Details
1. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9. [PubMed:8953513]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 22:59